This reflects the fact that a substantial proportion of the alterations were considered potentially actionable based on data from randomized trials in other tumor types, case reports, or preclinical studies (e.g., PIK3CA mutations in non‐breast tumors—Tier IIC). The gene discussed is PIK3CA; the disease is breast neoplasm.